Day: June 5, 2023

MONTREAL, June 05, 2023 (GLOBE NEWSWIRE) — Delmar International Inc. (www.delmarcargo.com), a world-renowned leader in logistics and supply chain solutions, expands into the dynamic markets of Pakistan and Sri Lanka. This strategic move further signifies Delmar’s commitment to providing leading global logistics and supply chain solutions to clients across the globe.

With a robust presence in over 15 countries to date and partnerships covering the globe, Delmar has built a strong reputation for delivering efficient, reliable and innovative freight forwarding and supply chain solutions. The expansion into Pakistan and Sri Lanka opens new avenues for growth, creating opportunities to better serve existing clients while also welcoming new partnerships in these thriving markets.

Pakistan and Sri Lanka hold immense potential for economic development, driven by their strategic geographical locations, expanding trade networks and growing consumer markets. By further establishing Delmar’s presence in these regions, Delmar aims to facilitate seamless trade flows, reduce supply chain complexities and enhance logistics capabilities for businesses operating within and beyond the region.

The expansion will enable Delmar to leverage its extensive global network, deep industry expertise and cutting-edge technology solutions to streamline freight forwarding operations to and from Pakistan and Sri Lanka. Clients can now benefit from a comprehensive range of logistics services, including but not limited to air freight, ocean freight and value-added logistics solutions tailored to their specific needs.

“We are excited to extend our footprint into Pakistan and Sri Lanka, two vibrant markets with tremendous growth potential. This strategic expansion aligns perfectly with our vision of providing seamless logistics services to our clients worldwide. We look forward to working closer with both local and international businesses and partners to support their supply chain needs, foster economic growth and contribute to the development of these regions.” – Robert Cutler, CEO, Delmar International Inc.

Delmar’s relentless commitment to excellence, customer satisfaction and operational efficiency positions it as the ideal logistics partner for businesses across diverse industries. The company’s expansion into Pakistan and Sri Lanka is an integral part of its long-term growth strategy, aimed at strengthening its global presence and supporting clients’ logistics requirements in growing key markets.

“We are extremely pleased with the addition of our new Sri Lanka and Pakistan locations. These new subsidiaries will complement our existing strong presence in India and Bangladesh. Delmar continues to witness a shift of global production to both the Southeast Asian and Indian subcontinent territories and will continue to expand rigorously in these markets to ensure that we continue to deliver superior service levels for our global customers.” – Mike Wagen, COO, Delmar International Inc.

Delmar Sri Lanka, Colombo
No. 385, 4th Floor, Land Mark Building
Kollupitiya, Galle Road, Colombo 03, Sri Lanka

Tel: +94 11 464 0250
Fax: +94 11 243 3 775

Delmar Pakistan, Karachi
Suite 101, 1st Floor, Ibrahim Trade Tower
Block 7 & 8, Maqbulabad Shahrah e Faisal Karachi, Pakistan

Tel: + 92-21-34327521-6
Fax: + 92-21-34327569

Click here for a list of Delmar International global offices.

About Delmar International Inc.

Established in 1965, Delmar International Inc. (www.delmarcargo.com) has evolved into a global leader in logistics and supply chain. Delmar offers comprehensive services such as customs brokerage, air freight, ocean freight, ground transportation, warehousing and supply chain consulting services.

Delmar remains strategically asset light. Diversification of its service offerings and vigorous expansion, including many acquisitions, has led to significant growth for Delmar in recent years. Today, Delmar operates across 17 countries globally and employs roughly 1500 people in over 45 cities.

Delmar International Inc.’s global headquarters are located in Lachine, Quebec, Canada.

Logistics Made Simple.

Media Contact:

Oliver Cutler, Chief Marketing Officer
Delmar International Inc. (Canada)
+1 (514) 636-8800
media@delmarcargo.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/95b35a77-f1d0-47ba-8a4e-fb546a3bac7b

GlobeNewswire Distribution ID 8851892

• NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for global markets
• Lotus Pharmaceuticals will acquire worldwide rights for NRX-101 for S-TRBD and will be responsible for commercialization of NRX-101 in markets outside the US through Lotus’s direct presence in certain Asian markets or through their export division, which currently has partnerships in numerous markets, including in Europe, Japan, China, Australia and Latin America
  
• Alvogen, through its CNS focused Almatica^® division, will be responsible for U.S. commercialization of NRX-101
• NRx will be eligible to receive up to $330 million in milestone payments tied to development progress and sales targets as well as tiered double-digit escalating to the mid-teens royalty payments contingent upon certain sales thresholds in the U.S. and a fixed royalty payment for markets outside the U.S.
• Agreement includes a right of first negotiation for new indications outside of the field of bipolar depression with suicidality for NRX-101 and/or potential new products containing D-cycloserine in combination with an antidepressant / antipsychotic

RADNOR, Pa. and MORRISTOWN, N.J. and TAIPEI, Taiwan, June 05, 2023 (GLOBE NEWSWIRE) — Lotus Pharmaceuticals (1795:TT; “Lotus”), a multinational pharmaceutical company, Alvogen, a privately owned U.S. based pharmaceuticals company, and NRx Pharmaceuticals Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals or NRx”), a clinical stage biopharmaceutical company, today announced a global collaboration agreement covering the development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for global markets.

Under the terms of the agreement, relating to NRX-101 for the U.S. market, NRx is entitled to receive an initial payment of $10 million upon achieving both a successful read-out from the ongoing Phase 2b/3 clinical trial in S-TRB and completion of a Type B meeting with the U.S. Food and Drug Administration (FDA). NRx would receive an additional payment of $5 million upon receipt of FDA approval for NRX-101 as well as bonus milestone payments of increasing amounts up to $330 million based on reaching certain net sales targets. In addition to success-based payments, NRx is eligible to receive a royalty on net sales between 12% and 16% contingent on certain sales thresholds for the U.S. market and other success-based payments for markets outside of the U.S.

Lotus will acquire worldwide rights for NRX-101 for treatment of S-TRBD and will be responsible for commercialization of NRX-101 in markets outside of the U.S. through their direct commercial presence in certain Asian markets or through Lotus’s export division where the company currently markets an extensive portfolio of products through top-tier partners. Lotus will partner with Alvogen, a longstanding partner for Lotus in the U.S., to commercialize NRX-101 for treatment of S-TRBD in the U.S. market through Alvogen’s Almatica label. Almatica is the CNS-focused division of Alvogen that currently markets six branded products. Alvogen and Lotus have committed to fund the next registrational study in suicidal treatment-resistant bipolar depression to support approval of NRX-101 contingent upon successful results of the ongoing Phase 2b/3 clinical trial and completion of a Type B meeting with the FDA. Lotus and Alvogen will have a right of first negotiation for new indications outside of the field of bipolar depression with suicidality for NRX-101 and/or potential new products containing D-cycloserine in combination with an antidepressant / antipsychotic.

Stephan Willard, J.D., Chief Executive Officer of NRx, commented, “This collaboration can accelerate the delivery of NRX-101 to patients grappling with suicidal bipolar depression who desperately need better treatment alternatives. With our current resources we believe we can fund our operations until the expected Phase 2b/3 trial data. This global partnership significantly minimizes the need for future capital raises for NRX-101 development and commercialization. Alvogen and Lotus, with their CNS expertise and global operational capabilities, are ideal partners for this and possibly other NRx programs.”

Lisa Graver, Chief Executive Officer of Alvogen, commented, “A medication that improves depression in bipolar patients with elevated risk of suicide would represent a significant improvement in treatment, and we view the Phase 2 STABIL-B data of NRX-101 as promising to that effect. This agreement is congruent with our strategy of developing branded CNS products with clear differentiation and patient benefit while leveraging our proven commercialization capabilities under our Almatica brand. NRX-101 provides an excellent addition to our growing CNS pipeline.”

Petar Vazharov, Chief Executive Officer of Lotus, commented, “This is an exciting transaction for Lotus. Over much of the last decade, Lotus has been able to transition itself from a domestic generics Taiwanese company into a global pharma company that exports its intellectual property all over the world through either our direct presence across Asia or through our export business that includes the U.S., Japan, China, Latin America and Europe. The addition of NRX-101 to our pipeline is completely in-line with our strategic objective to drive heightened innovation that addresses significant unmet medical needs.”

An estimated seven million people are living with bipolar depression in the U.S. alone¹. The risk of suicide within the group is very high, with data indicating that 50% or more of these patients will attempt suicide in their lifetime². There are currently no medications specifically approved for people with bipolar depression and elevated levels of suicidality. NRX-101 is the first investigational medication to be specifically studied in this vulnerable patient population. Proof-of-concept data from the Phase 2 STABIL clinical trial, in which patients with bipolar depression and acute suicidality were randomized to NRX-101 or lurasidone after stabilization with one infusion of ketamine, showed a statistically significant benefit of NRX-101 vs lurasidone. Based on these data, the U.S. FDA granted Breakthrough Therapy Designation (BTD) and a Special Protocol Assessment (SPA) for NRX-101 in bipolar depression with acute suicidality.

NRx Pharma recently announced that it has upgraded and expanded its ongoing Phase 2 randomized, controlled clinical trial in bipolar depression with sub-acute suicidality to a registrational Phase 2b/3 clinical trial.   Results from the ongoing Phase 2b/3 clinical trial are expected by year-end 2023. NRx will be hosting a conference call to discuss in greater detail the impact of the transaction.

About NRX-101

Up to 50% of individuals with bipolar disorder attempt suicide over their lifetime, and estimates indicate that up to 20% may succumb to suicide³. The only FDA-approved treatment for patients with treatment-resistant suicidal bipolar depression remains electroconvulsive therapy.

Conventional antidepressants can increase the risk of suicide in certain patients; hence their labels contain a warning to that effect. NRX-101 is a patented, oral, fixed dose combination of D-cycloserine and lurasidone, neither of which has shown addiction potential in preclinical models. Based on the results of a Phase 2 proof-of-concept study, NRX-101 received Breakthrough Therapy Designation from the FDA for the treatment of severe bipolar depression in patients with Acute Suicidal Ideation & Behavior (ASIB) after initial stabilization with ketamine or other effective therapy.

NRX-101 is one of the first oral antidepressants currently in late-stage clinical studies targeting the NMDA-receptor in the brain, which represents potentially a key new mechanism to treat depression with and without suicidality, as well as PTSD and other indications. To date, NRX-101 is the only oral NMDA investigational medicine focused on bipolar depression in patients with acute and sub-acute suicidality.

About NRx Pharmaceuticals

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically bipolar depression with suicidality and post-traumatic stress disorder (PTSD). The company’s lead program NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brain’s N-methyl-D-aspartate (NMDA) receptor and is being investigated in a Phase 2b/3 clinical trial for Suicidal Treatment-Resistant Bipolar Depression, which includes patients with both acute and sub-acute suicidality, an indication for which the only approved treatment is electroshock therapy. The company’s prior Phase 2 STABIL-B clinical trial evaluating NRX-101 in patients with Severe Bipolar Depression with Acute Suicidal Ideation & Behavior (ASIB) demonstrated a substantial improvement over available therapy in reducing depression and suicidality compared to placebo when patients were treated with NRX-101 after a single dose of ketamine. Based on the findings from the STABIL-B trial, the U.S. Food and Drug Administration (FDA) granted a Special Protocol Agreement and Breakthrough Therapy Designation for NRX-101 in patients with Severe Bipolar Depression with ASIB.

About Alvogen and Almatica

Alvogen is a privately held pharmaceutical company focused on developing, manufacturing and selling generic and branded products for the US market. The company has a diverse portfolio and pipeline that includes both branded and generic products across various administration forms. The Alvogen-family of companies includes Alvogen US (Generics), Almatica (Brands) and Almaject (Injectables).

Almatica Pharma LLC is a wholly owned subsidiary of Alvogen, Inc. and is a U.S. pharmaceutical company focused on the development, acquisition and commercialization of branded pharmaceutical products. Its current product portfolio covers a range of therapeutic areas, but promotional focus is on central nervous system disorders and conditions.

About Lotus

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.

¹Merikangas, K., et al.(2007). Lifetime and 12-Month Prevalence of Bipolar Spectrum Disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry, 64:543-552

²Pallaskorpi, et al. Incidence and Predictors of suicide attempts in bipolar I and II disorder: A 5-year follow-up study, Bipolar Disorders, 2016

³Psychiatric Times; Suicide Attempts and Completions in Patients with Bipolar Disorder

NRX Cautionary Note Regarding Forward-Looking Statements

This announcement of NRx Pharmaceuticals, Inc. includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company’s strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company’s management.

The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.

Lotus Cautionary Note Regarding Forward-Looking Statements

Except for historical information contained herein, the matters set forth in this document are forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are not based on historical facts but rather on management’s expectations regarding future growth, results of operations, performance, future capital and other expenditures, competitive advantages, business prospects and opportunities. Statements in this presentation about our future plans and intentions, results, level of activities, performance, goals or achievements or other future events constitute forward looking statements. Wherever possible, words such as “anticipate”, “believe”, “expect”, “may”, “could”, “will”, “potential”, “intend”, “estimate”, “should”, “plan”, “predict”, or the negative or other variations of statements reflect management’s current beliefs and assumptions and are based on the information currently available to our management. Investors are cautioned not to place undue reliance on these forward-looking statements, which are made as of the date of this document and we assume no obligation to update or revise any forward-looking statements.

Lotus Contacts:

INVESTOR AND MEDIA RELATIONS
Susan Liao, Head of Investor Relations
+886 2 2700 5908
investor@lotuspharm.com

NRX Contacts:

CORPORATE CONTACT
Matthew Duffy
Chief Business Officer
mduffy@nrxpharma.com

INVESTOR RELATIONS
Suzanne Messere
Investor Relations
suzanne.messere@sternir.com

Alvogen Contacts:

Andrea Sweet
andrea.sweet@alvogen.com

GlobeNewswire Distribution ID 1000823518

Effective at the Open of Market Trading Today, the Company Began Trading as Btab Ecommerce Group, Inc. (OTC: BBTT)

SYDNEY, Australia, June 05, 2023 (GLOBE NEWSWIRE) — Btab Ecommerce Group, Inc., a Georgia Corporation (the “Company”), announced that at the open of market trading today, June 5, 2023, its trading name on the OTC Markets changed from “American Seniors Association Holding Group, Inc.” to “Btab Ecommerce Group, Inc.” and its ticker symbol changed from “AMSA” to “BBTT.”

The Company is an e-commerce company with operations in Australia, Hong Kong, China, India, U.K., and the U.S. and its affiliated company and controlling shareholder is the e-commerce company, Btab Group Inc.

Find out more about the company at the official website https://btabcorp.com

About Btab Group Inc.

Btab was founded in 2014 and is an e-commerce company that operates through subsidiaries in Australia and the ASEAN region as well as locations in the US and UK. It provides affordable ecommerce services and supplies technology and products to small businesses to allow them to compete in an underserved market segment. The Btab network seeks to expand its reach into Europe and the Americas where it intends to provide small businesses with products and services not currently commercially available to them. Btab believes the e-commerce growth in Asia alone will be significant well into the next decade and beyond as increasing numbers of internet users take advantage of online shopping and increasing spending power.

Media Contact

Mr. Binson Lau, CEO
info@btabcorp.com
https://btabcorp.com         

GlobeNewswire Distribution ID 8852085

VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) — Kiplin Metals Inc. (TSX-V: KIP) (the “Company” or “Kiplin”) has observed a significant increase in activity surrounding its Cluff Lake Road (CLR) uranium project. Located in Saskatchewan, the project sits in a highly prospective area with neighbouring companies Orano Canada, Cameco Corp., Stallion Discovery Corp., and Canalaska Uranium Ltd.

One noteworthy development is the proximity of the CLR property to F3 Uranium Corp.’s (formerly Fission 3.0) Paterson Lake North (PLN) project. In November 2022, F3 discovered the JR high-grade uranium zone, and subsequent reports (refer to F3 press release dated Feb. 6, 2023) detailed intersections in drill hole PLN22-038, averaging 4.20 percent triuranium octoxide over 11.0 meters, including a high-grade interval of 9.8 percent U3O8 over 4.5 meters. This discovery implies the presence of a basement-hosted uranium deposit in the Athabasca region, comparable to Fission Uranium Corp.’s Triple R uranium deposit.

Kiplin believes that the combination of multiple EM (electromagnetic) conductors, magnetic lineaments, radon gas, and radioactivity anomalies on the CLR property makes it a highly prospective location for the discovery of a basement-hosted uranium deposit. The Company is enthusiastic about the project’s potential and opportunities for future exploration and development.

“We are encouraged by the increased activity and the presence of notable uranium projects in close proximity to our Cluff Lake Road Uranium project,” said Dr. Peter Born, Director of Kiplin. “The recent discoveries in the region further underline the prospectivity of the Athabasca Basin, and we believe that our CLR project holds significant potential for uncovering valuable uranium deposits.”

Kiplin remains committed to growing its exploration endeavours and leveraging the geological potential of the CLR project. The Company’s management and technical team actively evaluate the available data and formulate strategic plans for future exploration activities. Kiplin highlights that discoveries and observations on neighbouring properties do not necessarily indicate the presence of comparable mineralization or geological characteristics on the Company’s properties.

Dr. Peter Born, PGeo, is the designated qualified person as defined by National Instrument 43-101 and is responsible for, and has approved, the technical information contained in this release.

About Kiplin Metals Inc.
Kiplin Metals Inc. is a mineral exploration company. We create value for our shareholders by identifying and developing highly prospective mineral exploration opportunities. Our strategy is to advance our projects from discovery all the way to production. This vertically integrated strategy allows Kiplin to achieve exceptional shareholder value through the entire life-cycle of the mining process.

Cluff Lake Road Uranium Project. Kiplin Metals has the right to earn a one-hundred percent interest in the Cluff Lake Road Uranium Project (the “CLR Project”). The CLR Project covers ~531 ha in the southwestern Athabasca Basin in northern Saskatchewan, where several new discoveries have been made, including the Arrow and Triple R Uranium deposits. The CLR Project is 5 km east of the Cluff Lake Road (Hwy 955), which leads to the historic Cluff Lake Mine, which historically produced approximately 62,000,000 lbs of yellowcake uranium.

For further information, contact the Company at info@kiplinmetals.com or 604-622-1199 or visit the Company’s website at www.kiplinmetals.com.

On behalf of the Board,

Kiplin Metals Inc.

“Peter Born”
Director

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Contact Data

CONTACT:

MRKT360 INC

https://mrkt360.com

Alex Zertuche

alexz@mrkt360.com

For E.S.T Office Hours, Call 1 416-477-0587

An infographic accompanying this announcement is available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/aabdac10-161c-4707-baed-d2d982af0c5e

GlobeNewswire Distribution ID 8851651

VANCOUVER, British Columbia, June 05, 2023 (GLOBE NEWSWIRE) — VERSES AI Inc.  (CBOE CANADA:VERS) (OTCQX:VRSSF) (“VERSES” or the “Company”), a cognitive computing company specializing in the next generation of artificial intelligence (“AI”), announces the release on June 8, 2023 of an AI industry report titled “THE ROAD TO AUTONOMY: A Path To Global AI Governance”.

The report combines the legislative expertise from Dentons, the world’s largest multinational law firm, and the AI acumen of VERSES with the guidance on technical standards from the Spatial Web Foundation to provide an in-depth analysis of the legal and key legislative trends from across the world on the state of AI regulation and recommendations for a path forward for government regulation of AI.

The report aspires to pioneer a fresh approach for legal practitioners, government regulators, and lawmakers, to keep pace with the rapid technological advancements and to guide their adaptation. The critical aspect of the report is to promote the adoption of standards for what VERSES considers “law as code.” The objective is to encode laws and legal principles into an understandable, machine-readable language that will facilitate the comprehension and autonomous compliance of AI systems with legal frameworks and social norms.

The report analyzes the unprecedented challenges presented by the emergence of AI and autonomous software, devices, and vehicles addressing fundamental questions like, “How can governments regulate AI systems that are on a path to regulating themselves? How can humans stay in the loop to ensure AI alignment with human values, principles, and laws, while guaranteeing fair and equitable services for all individuals and communities? And, how do we encode and enforce AI laws directly in AI systems themselves?”

The report critically examines the transformative power of rapidly evolving technologies such as AI systems and their impending impact on legal, regulatory, and government sectors and accentuates the crucial need for developing and adopting standards that foster the understanding, governance, and interoperability of AI and autonomous systems. The report underscores the role of these technical standards in shaping dynamic and effective laws to regulate, oversee, and contemporize AI activities.

The goal of the report is to provide governments, regulators, and legislators with a pragmatic framework that not only informs but also provides a roadmap for policymaking, legislation, and compliance efforts in the field of AI. This is relevant to the flourishing autonomous vehicle industry, while also serving as a fundamental guide for all future AI-driven systems. Emphasizing the urgency of a globally unified, forward-thinking approach to AI governance, the report signals the vital need for standards development and deployment as the world navigates the pathway to Autonomous Intelligent Systems (“AIS”).

Significantly, the report points to the instrumental role of sociotechnical standards, as demonstrated by the work of the Institute of Electrical And Electronics Engineers IEEE P2874 Working Group. This initiative from the world’s largest association of technical professionals, underscores the importance of aligning AIS with human values and reducing the risk of harmful behavior.

The report also highlights the European Commission’s Flying Forward 2020 (“FF2020”) project for successfully implementing these standards. Led by VERSES and running on its KOSM platform, the FF2020 project featured autonomous AI-powered drones executing various tasks, such as medical supply delivery, building security inspection, and large crowd monitoring, all while adhering to local laws. The project exemplifies how the seamless integration of standards for AI with Urban Air Mobility and current legal and regulatory frameworks could improve the implementation of AI-powered services at city scale and beyond.

The report envisions the application of these standards to a host of sectors, including healthcare, education, finance, supply chain and more, paving the way for a smarter world with AI seamlessly operating behind the scenes.

“AI is advancing at an unprecedented pace, raising concerns about the direction of its future trajectory. As AI evolves towards autonomous systems, the need for regulation becomes critical. We must address the challenge of regulating self-regulating AI to ensure alignment with human values and prevent potential risks. By implementing global technical standards and establishing an international AI regulatory framework, we can harness the immense benefits of AI while safeguarding against its potential perils,” stated VERSES CEO, Gabriel René.

“We are thrilled to collaborate with VERSES, as the challenge of regulating machines raises the question of how to strike a balance between control and freedom for entities incapable of comprehending laws or guiding principles. The current pace of the legal system hinders effective regulation and allows unchecked development of rapidly evolving technologies like AI. A new socio-technological standards-based approach seems to be a very pragmatic and appealing way forward,” said Peter Stockberger, Partner at Dentons US.

In summary, the report calls for a safe, effective, and inclusive journey down the “Road to Autonomy,” ensuring that future AI systems are not just technically advanced but also aligned with the best interests of humanity, both now and in the future. With AI influencing every sector, this insightful report offers pragmatic recommendations for a more secure, innovative, and integrated AI-driven future. The full report will be available on the VERSES, DENTONS, and Spatialweb.org websites on or around June 8, 2023, with the executive summary already available for preview.

About VERSES

VERSES is a cognitive computing company specializing in next-generation AI. Modeled after natural systems and the design principles of the human brain and the human experience, VERSES flagship offering, GIA, is an Intelligent Assistant for everyone powered by KOSMOS, a network operating system enabling distributed intelligence.  Built on open standards, KOSM transforms disparate data into knowledge models that foster trustworthy collaboration between humans, machines, and AI, across digital and physical domains. Imagine a smarter world that elevates human potential through innovations inspired by nature. Learn more at VERSES, LinkedIn, and Twitter.

About Dentons 
Dentons is designed to be different. As the world’s largest global law firm with 21,000 professionals in over 200 locations in more than 80 countries, Denton’s can help you grow, protect, operate and finance your business. Denton’s polycentric and purpose-driven approach, together with their commitment to inclusion, diversity, equity and ESG, ensures they challenge the status quo to stay focused on what matters most to you. www.dentons.com

About the Spatial Web Foundation 
The Spatial Web Foundation is a non-profit organization dedicated to the development and ethical use of technology, specifically in the creation and implementation of the Spatial Web protocol. The foundation’s core initiatives include developing open standards and protocols, promoting interoperability, and educating the public and policymakers. The foundation supports transparency and accountability in the development and use of technology, promotes responsible innovation, engages in dialogue and collaboration with various stakeholders, and adopts a proactive approach to addressing emerging ethical challenges. Ultimately, the Spatial Web Foundation seeks to create a more inclusive, accessible, and equitable internet that empowers individuals and communities to connect, create, and thrive.

On Behalf of the Company 

Gabriel René
VERSES Technologies Inc.
Co-Founder & CEO
press@verses.io

Media and Investor Relations Inquiries 

Leo Karabelas
Focus Communications
President
info@fcir.ca
416-543-3120

The NEO has not reviewed or approved this press release for the adequacy or accuracy of its contents.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1df22be2-a8db-4ce3-8217-05fbc905429f

GlobeNewswire Distribution ID 8852013